Xiaoguang Margaret Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xiaoguang Margaret Liu has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
- Lufang Zhou
The Ohio State University 2 Department of Biomedical Engineering Columbus, Ohio
75 shared publications - Jiashuai Zhang
The Ohio State University 2 Department of Biomedical Engineering Columbus, Ohio
53 shared publications - Zhuoxin Zhou
The Ohio State University 1 Department of Chemical and Biomolecular Engineering Columbus, Ohio
53 shared publications - Yingnan Si
Department of Biomedical Engineering, University of Alabama at Birmingham (UAB), 1825 University Blvd, Birmingham, AL 35294, USA
47 shared publications - Kai Chen
Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, Ohio
39 shared publications - Seulhee Kim
Department of Biomedical Engineering, The Ohio State University, Columbus, Ohio
39 shared publications
Latest Publications
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF15
Humanized Antibody–Drug Conjugates for Somatostatin Receptor 2–Positive Tumor Treatment
Somatostatin receptor 2 (SSTR2) is overexpressed in neuroendocrine tumors (NET) and meningiomas. The objective of this study was to develop an SSTR2-targeted therapy to treat both tumors. We developed a humanized anti-SSTR2 monoclonal antibody (mAb) demonstrating strong cancer cell binding, internalization in cancer cells, and tumor specificity, as evidenced by flow cytometry, confocal microscopy, and live-animal imaging. Antibody–drug conjugates were generated by conjugating the SSTR2 mAb with potent payloads, including monomethyl auristatin F or mertansine. In vitro assessments revealed high cytotoxicity across NET subtypes and meningioma cell lines. In vivo efficacy was confirmed in two mouse models, that is, subcutaneous NET xenografts and intracranial meningioma xenografts, in which treatment inhibited proliferation, induced apoptosis and cell death, exhibited minimal toxicity, and extended survival. The mechanism of action was further elucidated through bulk RNA sequencing after treatment. These findings highlight the therapeutic potential of our humanized SSTR2 mAb for targeted payload delivery in NETs and meningiomas.
- 3 August 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF15
Open AccessHumanized Antibody–Drug Conjugates for Somatostatin Receptor 2–Positive Tumor Treatment
Somatostatin receptor 2 (SSTR2) is overexpressed in neuroendocrine tumors (NET) and meningiomas. The objective of this study was to develop an SSTR2-targeted therapy to treat both tumors. We developed a humanized anti-SSTR2 monoclonal antibody (mAb) demonstrating strong cancer cell binding, internalization in cancer cells, and tumor specificity, as evidenced by flow cytometry, confocal microscopy, and live-animal imaging. Antibody–drug conjugates were generated by conjugating the SSTR2 mAb with potent payloads, including monomethyl auristatin F or mertansine. In vitro assessments revealed high cytotoxicity across NET subtypes and meningioma cell lines. In vivo efficacy was confirmed in two mouse models, that is, subcutaneous NET xenografts and intracranial meningioma xenografts, in which treatment inhibited proliferation, induced apoptosis and cell death, exhibited minimal toxicity, and extended survival. The mechanism of action was further elucidated through bulk RNA sequencing after treatment. These findings highlight the therapeutic potential of our humanized SSTR2 mAb for targeted payload delivery in NETs and meningiomas.
- Open Access
- 24 July 2026
- Published by Elsevier in Cell Reports Medicine
- Vol. 7 (8) , 102934
Combine antibody-drug conjugate with cmLumiOpto for triple-negative breast cancer treatment
- 24 July 2026
- Published by Elsevier in Cell Reports Medicine
- Vol. 7 (8) , 102934
Open AccessCombine antibody-drug conjugate with cmLumiOpto for triple-negative breast cancer treatment
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from Advanced CD276-Targeting Dual-Payload Antibody–Drug Conjugates for Cancer Therapy
Characterization of CD276 expression and evaluation of humanized CD276 mAb binding and cross-species specificity. A, TCGA mRNA and protein analysis of CD276 expression in normal breast and breast cancers. **, P < 0.01; ***, P < 0.001. B, Representative image showing high CD276 expression in human TNBC tissue. Scale bar equals 70 μm. C, Representative IHC images of human normal organs stained with our humanized CD276 mAb. Scale bar equals 70 μm. D, Representative IHC images of monkey, mouse, and rat normal organs stained with humanized CD276 mAb. Scale bar equals 70 μm. E, Binding affinity (KD values) of humanized CD276 mAb for CD276 receptors from human, monkey, mouse, and rat. F, Flow cytometry analysis of humanized CD276 mAb binding to the surface of human and mouse TNBC cells and rat breast cancer cells. SSC, side scatter.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Advanced CD276-Targeting Dual-Payload Antibody–Drug Conjugates for Cancer Therapy
Characterization of CD276 expression and evaluation of humanized CD276 mAb binding and cross-species specificity. A, TCGA mRNA and protein analysis of CD276 expression in normal breast and breast cancers. **, P < 0.01; ***, P < 0.001. B, Representative image showing high CD276 expression in human TNBC tissue. Scale bar equals 70 μm. C, Representative IHC images of human normal organs stained with our humanized CD276 mAb. Scale bar equals 70 μm. D, Representative IHC images of monkey, mouse, and rat normal organs stained with humanized CD276 mAb. Scale bar equals 70 μm. E, Binding affinity (KD values) of humanized CD276 mAb for CD276 receptors from human, monkey, mouse, and rat. F, Flow cytometry analysis of humanized CD276 mAb binding to the surface of human and mouse TNBC cells and rat breast cancer cells. SSC, side scatter.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Advanced CD276-Targeting Dual-Payload Antibody–Drug Conjugates for Cancer Therapy
Figure S2 shows single ADCs structure and HPLC characterization.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Advanced CD276-Targeting Dual-Payload Antibody–Drug Conjugates for Cancer Therapy
Figure S2 shows single ADCs structure and HPLC characterization.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 6 from Advanced CD276-Targeting Dual-Payload Antibody–Drug Conjugates for Cancer Therapy
In vivo anti-TNBC efficacy of DualADCs in 4T1-Fluc xenograft immunocompetent mouse models. ADCs or saline (16 mg/kg) were i.v. injected via the tail vein. A, Tumor volume measurement with black arrows indicating treatments or saline (n = 4). B, Body weight. C, H&E staining of tumor tissues. Scale bar equals 70 μm. D, H&E staining of major organs (heart, liver, spleen, lung, and kidney) collected at the endpoint of the in vivo study. Scale bar equals 70 μm.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 6 from Advanced CD276-Targeting Dual-Payload Antibody–Drug Conjugates for Cancer Therapy
In vivo anti-TNBC efficacy of DualADCs in 4T1-Fluc xenograft immunocompetent mouse models. ADCs or saline (16 mg/kg) were i.v. injected via the tail vein. A, Tumor volume measurement with black arrows indicating treatments or saline (n = 4). B, Body weight. C, H&E staining of tumor tissues. Scale bar equals 70 μm. D, H&E staining of major organs (heart, liver, spleen, lung, and kidney) collected at the endpoint of the in vivo study. Scale bar equals 70 μm.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table 1 from Advanced CD276-Targeting Dual-Payload Antibody–Drug Conjugates for Cancer Therapy
DAR distribution, average DAR, and DDR of single-payload ADCs and DualADCs.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Advanced CD276-Targeting Dual-Payload Antibody–Drug Conjugates for Cancer Therapy
DAR distribution, average DAR, and DDR of single-payload ADCs and DualADCs.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Advanced CD276-Targeting Dual-Payload Antibody–Drug Conjugates for Cancer Therapy
Figure S7 shows bulk RNA-Seq analysis of immune functions in TME.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Advanced CD276-Targeting Dual-Payload Antibody–Drug Conjugates for Cancer Therapy
Figure S7 shows bulk RNA-Seq analysis of immune functions in TME.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Advanced CD276-Targeting Dual-Payload Antibody–Drug Conjugates for Cancer Therapy
Figure S6 shows in vitro cytotoxicity evaluation at low drug concentrations.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Advanced CD276-Targeting Dual-Payload Antibody–Drug Conjugates for Cancer Therapy
Figure S6 shows in vitro cytotoxicity evaluation at low drug concentrations.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Advanced CD276-Targeting Dual-Payload Antibody–Drug Conjugates for Cancer Therapy
Figure S3 shows evaluation of cancer surface binding by DualADCs.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Advanced CD276-Targeting Dual-Payload Antibody–Drug Conjugates for Cancer Therapy
Figure S3 shows evaluation of cancer surface binding by DualADCs.